Bruton's Tyrosine Kinase Inhibitors for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.
Document Type
Article
Publication Title
Journal of cutaneous medicine and surgery
Abstract
Although second-generation H1 antihistamines remain the first-line treatment for chronic spontaneous urticaria (CSU), a significant proportion of patients experience inadequate symptom control, highlighting the ongoing need for more effective and targeted treatment strategies. We conducted a systematic review and meta-analysis of 5 randomized controlled trials (RCTs) comparing Bruton's tyrosine kinase (BTK) inhibitors with placebo at 4, 8, and 12 weeks in patients with CSU. We searched PubMed, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) from inception to April 2025. The primary outcomes assessed included the Weekly Urticaria Activity Score (UAS7), complete absence of pruritus and urticaria (UAS7 = 0), well-controlled CSU (UAS7 ≤ 6), and safety outcomes. Across 5 included RCTs, 1071 (71.93%) patients received BTK inhibitors. BTK inhibitors significantly increased the likelihood of achieving UAS7 = 0 at week 4 [risk ratio (RR) 5.64; 95% confidence interval (CI) 1.04-30.70;
First Page
12034754261418239
Last Page
12034754261418239
DOI
10.1177/12034754261418239
Publication Date
4-17-2026
Recommended Citation
Cevallos-Cueva M, Ghanem L, Kuceki G, Onejeme C, Sicorschi Gutu C, Mendoza-Millán DL, Fernandez-Faith E. Bruton's Tyrosine Kinase Inhibitors for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis. J Cutan Med Surg. 2026 Apr 17:12034754261418239. doi: 10.1177/12034754261418239. Epub ahead of print. PMID: 41999021.